PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Clinical and Experimental Rheumatology0 citationsOpen Access

Janus kinase inhibitors therapy in idiopathic inflammatory myopathies: a case series

AVAna Luís VasconcelosAMAntónio MarinhoACAna Campar

Key Points

  • Patients treated with JAK inhibitors showed clinical improvement, particularly in interstitial lung disease.
  • JAKi treatment demonstrated a notable steroid-sparing effect, enhancing patient management options.
  • Observational analysis of refractory idiopathic inflammatory myopathies used JAK inhibitors to assess effectiveness and safety.
  • Future studies are necessary to confirm the results and expand understanding of JAK inhibitors' role in therapy.

Abstract

JAKi therapy appears to be clinically effective, well tolerated, and safe in patients with refractory IIM, with a particular benefit in ILD. The steroid sparing effect was also a major outcome. Future prospective and controlled studies are warranted to confirm these preliminary results and better define the therapeutic potential of JAKi in IIM.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Vasconcelos et al. (2025) studied this question.

synapsesocial.com/papers/69a75d9dc6e9836116a27cb8https://doi.org/10.55563/clinexprheumatol/0yu9gm
Ask AI
Helpful
Bookmark
Share
View Full Paper